



IFITM3, FURIN, ACE1, and TNF- α Genetic Association With COVID-19 Outcomes: Systematic Review and Meta-Analysis

João Locke Ferreira de Araújo, Diego Menezes, Renato Santana de Aguiar and Renan Pedra de Souza*

Grupo de Pesquisa em Bioestatística e Epidemiologia Molecular, Laboratório de Biologia Integrativa, Programa de Pós Graduação em Genética, Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

OPEN ACCESS

Edited by:

José M. Álvarez-Castro,
University of Santiago de Compostela,
Spain

Reviewed by:

Martha Guevara-Cruz,
Instituto Nacional de Ciencias Médicas
y Nutrición Salvador Zubirán
(INCMNSZ), Mexico
Gagandeep Kaur,
University of Rochester, United States

*Correspondence:

Renan Pedra de Souza
renanrps@ufmg.br

Specialty section:

This article was submitted to
Applied Genetic Epidemiology,
a section of the journal
Frontiers in Genetics

Received: 13 September 2021

Accepted: 11 February 2022

Published: 01 April 2022

Citation:

de Araújo JLF, Menezes D, Aguiar RSD
and Souza RPd (2022) IFITM3, FURIN,
ACE1, and TNF- α Genetic Association
With COVID-19 Outcomes: Systematic
Review and Meta-Analysis.
Front. Genet. 13:775246.
doi: 10.3389/fgene.2022.775246


Human polymorphisms may contribute to SARS-CoV-2 infection susceptibility and COVID-19 outcomes (asymptomatic presentation, severe COVID-19, death). We aimed to evaluate the association of *IFITM3*, *FURIN*, *ACE1*, and *TNF- α* genetic variants with both phenotypes using meta-analysis. The bibliographic search was conducted on the PubMed and Scielo databases covering reports published until February 8, 2022. Two independent researchers examined the study quality using the Q-Genie tool. Using the Mantel–Haenszel weighted means method, odds ratios were combined under both fixed- and random-effect models. Twenty-seven studies were included in the systematic review (five with *IFITM3*, two with *Furin*, three with *TNF- α* , and 17 with *ACE1*) and 22 in the meta-analysis (*IFITM3* $n = 3$, *TNF- α* , and *ACE1* $n = 16$). Meta-analysis indicated no association of 1) *ACE1* rs4646994 and susceptibility, 2) *ACE1* rs4646994 and asymptomatic COVID-19, 3) *IFITM3* rs12252 and ICU hospitalization, and 4) *TNF- α* rs1800629 and death. On the other hand, significant results were found for *ACE1* rs4646994 association with COVID-19 severity (11 studies, 692 severe cases, and 1,433 nonsevere controls). The *ACE1* rs4646994 deletion allele showed increased odds for severe manifestation (OR: 1.45; 95% CI: 1.26–1.66). The homozygous deletion was a risk factor (OR: 1.49, 95% CI: 1.22–1.83), while homozygous insertion presented a protective effect (OR: 0.57, 95% CI: 0.45–0.74). Further reports are needed to verify this effect on populations with different ethnic backgrounds.

Systematic Review Registration: https://www.crd.york.ac.uk/prosperodisplay_record.php?ID=CRD42021268578, identifier CRD42021268578

Keywords: polymorphism, genetic association study, candidate genes, transposable elements, biomarkers, host genetics

INTRODUCTION

Coronavirus disease 2019 (COVID-19) clinical presentation is heterogeneous, ranging from entirely asymptomatic up to severe cases and death. Another level of heterogeneity is observed regarding persistent symptoms: one study has estimated that the median proportion of individuals who experienced at least one persistent symptom was 73% (Nasserie et al., 2021). Uncovering biomarkers



linking patients with distinct prognosis subgroups would be beneficial. Different strategies have been employed to uncover molecular markers predicting odds for better prognosis and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection susceptibility. Proteins, lipids, and metabolites have already been examined (Praisman and Wells, 2021; Samprathi and Jayashree, 2021). Genetic variability has been shown to be a valuable source for biomarker research. COVID-19 prognosis and infection susceptibility are multifactorial traits determined by the complex interaction of environmental factors and multiple genes. Thus, significant single-gene results may lead to substantial predictors such as the C-C chemokine receptor type five (*CCR5*) gene association with HIV susceptibility and prognosis (Liu et al., 2012), or ABO blood type and dengue severity (Hashan et al., 2021).

Genetic association studies can be designed within prespecified genes of interest (candidate gene approach) or with a broader strategy characterizing diversity across large genomic areas (genome-wide association studies, whole exome and genome sequencing). Angiotensin-converting enzyme 2 (*ACE2*), transmembrane serine protease 2 (*TMPRSS2*), human leukocyte antigen (*HLA*), interferon-induced transmembrane protein 3 (*IFITM3*), tumor necrosis factor-alpha (*TNF- α*), *FURIN*, and angiotensin I-converting enzyme (*ACE1*) were the most studied genes using the candidate gene approach in 2020 (Araújo et al., 2021). They all present strong biological plausibility since they act on viral cell entry or human immune response to SARS-CoV-2.

Findings from single association studies must always be considered carefully because of the likelihood of producing spurious outcomes (Sullivan, 2007). Replication is essential before considering using genetic markers in the clinical setting. Although that has been proved hard, inconsistency frequently can be attributed to shortfalls in study design, implementation, and interpretation, with inadequately powered sample groups being of significant concern (Hattersley and McCarthy, 2005). A systematic meta-analytic approach may support estimating population-wide effects of genetic risk factors in human diseases (Ioannidis et al., 2001). The PROSPERO (Moher et al., 2014) database, indicating protocols for systematic reviews, has already been presented for *HLA* (CRD42021251670) (Deb et al., 2022), *ACE2*, and *TMPRSS2* (CRD42021229963) contribution with COVID-19 outcomes. Therefore, we focused our systematic review on *IFITM3*, *FURIN*, *ACE1*, and *TNF- α* genetic variants and their association with COVID-19 susceptibility and prognosis to reduce unnecessary duplication.

IFITM3 (MIM 605579; 11p15.5) is a protein-coding gene that disturbs cell entry by inhibiting viral fusion with cholesterol-depleted endosomes (Amini-Bavil-Olyaei et al., 2013); a mechanism also described during SARS-CoV-2 infection (Prelli Bozzo et al., 2021). The *IFITM3* rs12252 polymorphism has been associated with influenza severity (Prabhu et al., 2018). The *TNF* (MIM 191160; 6p21.33) gene encodes a multifunctional proinflammatory cytokine. Although *TNF- α* is not as relevant as

TABLE 1 | Association studies of *ACE1* rs4646994 (Alu 287 pb) with coronavirus disease 2019 (COVID-19) susceptibility included in the systematic review.

Year	Author	Sample					Control		Case	
		Date	Place	Ethnic background	Size	Male n(%)	n	Criteria	n	Criteria
2020	Gómez	—	Spain	Caucasian (Asturias)	740	373 (0.50)	536	Healthy population	204	COVID-19 positive
2021	Akbari	2020	Iran	—	182	105 (0.57)	91	Unaffected individuals without a history of exposure to COVID-19 cases	91	COVID-19 positive
	Aladag	May/2020	Turkey	—	412	—	300	General population	112	COVID-19 positive
	Annunziata	March–April/20	Italy	Southern Italians	39	—	19	Healthy subjects	20	COVID-19 positive
	Hubacek	March–June/2020	Czech Republic	—	2,989	—(0.54)	2,579	General population	408	COVID-19 positive
	Kouhpayeh	May–September/2020	Iran	—	520	276 (0.55)	258	Healthy subjects with negative PCR and clinical diagnostic criteria	244	COVID-19 positive
	Mahmood	October–December/2020	Iraq	—	195	—(0.50)	96	Healthy subjects with negative serological test	99	COVID-19 positive
	Mir	September/2020–April/2021	Saudi Arabia	—	267	185 (0.69)	150	Healthy subjects	117	COVID-19 positive
	Möhlendick	March–September/2020	Germany	—	550	323 (0.59)	253	Patients with COVID-19 symptoms with negative PCR	297	COVID-19 positive
Saad	—	Lebanon	Lebanese	387	195 (0.50)	155	Participants with negative PCR	232	COVID-19 positive	
2022	Gong	January–March/2020	China	—	862	—	441	Healthy subjects	421	COVID-19 positive
	Papadopoulou	March–June/2020	Greece	Caucasian (Greek)	389	—	316	Blood product donors and volunteer healthcare workers	73	COVID-19 positive

interleukin-6 on the cytokine storm presented in severe COVID-19 patients (Karki and Kanneganti, 2021), anti-TNF- α drug repositioning for COVID-19 has been proposed (Stebbing et al., 2020). *FURIN* is coded by the *FURIN* (MIM 136950; 15q26.1) gene. It regulates constitutive exocytic and endocytic pathways and has a central role in SARS-CoV-2 transmission (Peacock et al., 2021). The *ACE1* (MIM 106180; 17q23.3) gene produces a protein related to blood pressure regulation and electrolyte balance, and *ACE1/ACE2* balance has been suggested to play a pivotal role in the pathobiology and treatment of COVID-19 (Sriram and Insel, 2020). The *ACE1* rs4646994 variant is a 287-bp Alu repeat insertion/deletion (indel) on intron 16 known to alter *ACE-1* levels and influence several clinical traits (Castellon and Hamdi, 2007). Here, we present the result of a systematic review and, whenever possible, a meta-analysis of *IFITM3*, *FURIN*, *ACE1*, and *TNF- α* genetic association with susceptibility to SARS-CoV-2 infection and COVID-19 severity.

MATERIALS AND METHODS

The systematic review protocol was submitted to PROSPERO (CRD42021268578). Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) was adopted as a guideline for reporting this systematic review (Page et al., 2021). The study selection was carried out in three phases: identification, screening,


and eligibility. Search on the PubMed and Scielo databases led to article identification. The PECO question for prognosis was Participants (P) = subjects with COVID-19, Exposition (E) = minor alleles, Control (C) = major alleles of genetic variants, and Outcomes (O) = COVID-19 severity (asymptomatic or severe presentation); while the PECO question for susceptibility was P = overall population, E = minor alleles, C = major alleles of genetic variants, and Outcomes (O) = COVID-19 positive diagnosis. The bibliographic search included all studies published until February 8, 2022, with no language restriction, using the search arguments listed in **Supplementary Material SI**. Two independent researchers conducted article screening. Inclusion criteria were primary articles covering genetic association of COVID-19 susceptibility or prognosis with *IFITM3*, *FURIN*, *ACE1*, and *TNF- α* variants, comprising four separate searches. Exclusion criteria were review articles or primary articles evaluating the association of COVID-19 susceptibility or prognosis with other genes.

We assessed study quality using the Q-Genie tool (Sohani et al., 2016) performed by two independent researchers. This instrument contains 11 questions to be marked on a seven-point Likert scale examining several aspects of a genetic association study: scientific basis for the development of the research question, ascertainment of comparison groups (e.g., cases and controls), technical and nontechnical classification of tested genetic variants (e.g., genotyping call rates, blinded experiments), classification of the outcome (e.g., sampling

TABLE 2 | Association studies of *ACE1* rs4646994 (Alu 287 pb) with COVID-19 prognosis included in the systematic review.

Phenotype	Year	Author	Sample					Control		Case	
			Date	Place	Ethnic background	Size	Male n(%)	n	Criteria	n	Criteria
Asymptomatic × symptomatic	2021	Cafiero	—	Italy	—	104	58 (0.56)	50	Asymptomatic	54	Symptomatic (x-ray imaging)
		Hubacek	March–June/2020	Czech Republic	—	408	—(0.55)	163	Asymptomatic	245	Symptomatic (no hospitalization)
		Gunal	April–July/2020	Turkey	—	60	—	30	Asymptomatic	30	Severe (RR ≥30/min; SpO ₂ ≤93%; PaO ₂ /FiO ₂ ≤300 mmHg; mechanical ventilation or ICU)
Nonsevere × severe	2020	Gómez	—	Spain	Caucasian (Asturias)	204	125 (0.61)	137	Mild (hospitalized, nonsevere)	67	Severe (hospitalized, mechanical ventilation and/or ICU)
		Akbari Aladag	2020	Iran	—	91	53 (0.58)	54	Hospitalized, non-ICU	37	Hospitalized, ICU
	May/2020		Turkey	—	65	-	53	Nonsevere	12	Severe (fever or suspected respiratory infection, plus one of the following: RR >30/min; severe respiratory distress; or SpO ₂ ≤93%)	
	Çelik	—	Turkey	—	154	78 (0.50)	119	Mild (outpatients) and moderate (hospitalized nonsevere)	35	Severe (RR ≥30/min; SpO ₂ ≤93%; PaO ₂ /FiO ₂ ≤300 mmHg; mechanical ventilation or ICU)	
											Gunal
	Kouhpayeh	May–September/2020	Iran	—	258	144 (0.56)	106	Nonsevere	152	Severe (fever or suspected respiratory infection, plus one of the following: RR >30/min; severe respiratory distress; or SpO ₂ ≤93%)	
											Mahmood
	Möhlendick	March–September/2020	Germany	—	251	176 (0.59)	207	Mild and hospitalized (non-ICU)	44	Severe (hospitalized, mechanical ventilation and/or ICU)	
											Saad
	Verma	August–September/2020	India	India	269	174 (0.65)	149	Mild (RR <24/min, SpO ₂ >94%)	120	Severe (pneumonia with RR > 30/min; severe respiratory distress; or SpO ₂ ≤93%)	
Gong Papadopoulou											January–March/2020
	March–June/2020	Greece	Caucasian (Greek)	81	43 (0.53)	29	Mild and moderate (with symptoms of pneumonia and no signs of severe pneumonia)	52	Severe or critical (fever or suspected respiratory infection, plus one of the following: RR >30/min; severe respiratory distress; or SpO ₂ ≤93%)		
Alive × dead										2021	Mir
	Möhlendick	March–September/2020	Germany	—	297	176 (0.59)	251	Mild, hospitalized (non-ICU) and severe	46		


Note. RR, respiratory rate; ICU, intensive care unit; SpO₂, oxygen saturation; PaO₂/FiO₂, arterial oxygen pressure/fraction of inspired oxygen; CT, computerized tomography.



strategy, definition criteria), discussion of sources of bias, appropriateness of sample size, description of planned statistical analyses, statistical methods applied, test of assumptions in the genetic studies (e.g., Hardy-Weinberg equilibrium), and appropriate interpretation of the results.

Proposed cutoffs for understanding are ≤ 35 poor, > 35 moderate, and ≥ 45 good quality, with the total score ranging from 7 to 77 points.

Meta-analysis was conducted whenever three or more studies were included for the same polymorphism and outcome. We



carried out single meta-analyses for each polymorphism considering allelic and genotypic effects (under both allele recessive model assumptions). Heterogeneity between studies was assessed using the chi-square test. We used the *metabin* function coded on *meta* package in R (version 4.1.0) (R Core Team, 2014) to estimate overall odds ratios (ORs) and its 95% confidence interval (CI). Original ORs were combined using the Mantel–Haenszel weighted means method under both fixed- and random-effect models. The significance level was set at 0.05.

RESULTS

Twenty-seven studies were included in the systematic review: five with *IFITM3* (Zhang et al., 2020; Alghamdi et al., 2021; Cuesta-Llavona et al., 2021; Gómez et al., 2021; Schönfelder et al., 2021), two with *Furin* (Latini et al., 2020; Torre-Fuentes et al., 2021), three with *TNF-α* (Saleh et al., 2020; Fishchuk et al., 2021; Heidari Nia et al., 2021), and 17 with *ACE1* (Gómez et al., 2020; Aladag et al., 2021; Annunziata et al., 2021; Cafiero et al., 2021; Gunal et al., 2021; Hubacek et al., 2021; Karakaş Çelik et al., 2021; Kouhpayeh et al., 2021; Mir et al., 2021; Möhlendick et al., 2021; Saad et al., 2021; Verma et al., 2021; Akbari et al., 2022; Gong

et al., 2022; Mahmood et al., 2022; Papadopoulou et al., 2022). (Figure 1). Inconsistencies in reported frequencies were found in two studies (Gómez et al., 2021; Karakaş Çelik et al., 2021).

All manuscripts but one reached moderate or good quality scores in the Q-Genie analysis (**Supplementary Material S1**). Among the 11 questions, it is clear that all studies had the worst performance for questions number 5 and 10. While question 5 examines reported information regarding how genotyping was conducted (e.g., blinded experiments, batch effects), question 10 evaluated whether genetic relationships among subjects were tested, and sex and ethnicity were stated.

Five meta-analyses were carried out, including 22 studies evaluating three genes (*IFITM3* $n = 3$, *TNF-α* $n = 3$, and *ACE1* $n = 16$). Twelve studies, including 2,318 control subjects and 5,194 COVID-19 positives, evaluated the *ACE1* rs4646994 association with COVID-19 susceptibility (**Table 1**). Significant heterogeneity was observed for all genetic models with no significant association under the random model (**Figure 2**). Similar findings were detected in the meta-analysis of the *ACE1* rs4646994 variant with asymptomatic presentation (**Table 2**), indicating no significant effect pooled from three studies (**Figure 3**). We observed high heterogeneity in the sampling places and reported ethnic backgrounds.




FIGURE 4 | Forest plot illustrating *ACE1* rs4646994 (Alu 287 pb) association with COVID-19 severity (severe × others). Significant allelic and genotypic effects were observed. Case and control definitions are presented in **Table 2**. **(A)** D-allele model. D-allele was associated with increased risk of COVID-19 severity. **(B)** D recessive model. D/D genotype carriers showed increased odds to manifest severe COVID-19 compared with D/I and I/I carriers combined **(C)** I recessive model. I/I genotype carriers showed decreased odds to present severe COVID-19 compared with D/I and D/D carriers combined.

We were able to conduct a meta-analysis investigating whether *ACE1* rs4646994 polymorphism could predict COVID-19 severity. Eleven studies were included reaching a total of 692

individuals with severe COVID-19 and 1,433 with nonsevere manifestation (**Table 2**). The allelic association was observed with increased odds for deletion (D) allele compared with I-allele

TABLE 3 | Association studies of *IFITM3* rs12252 with COVID-19 prognosis included in the systematic review.

Phenotype	Year	Author	Sample					Control		Case	
			Date	Place	Ethnic background	Size	Male n(%)	n	Criteria	n	Criteria
Non-ICU × ICU	2021	Alghamdi	—	Saudi Arabia	Saudi	376	112 (0.56)	210	Hospitalized, non-ICU	166	Hospitalized, ICU
	2021	Cuesta-Llavona	March–December/2020	Spain	Caucasian (Asturias)	484	276 (0.57)	332	Hospitalized, non-ICU	152	Hospitalized, ICU
	2021	Gómez	March–August/2020	Not informed	Caucasian (Asturias)	311	174 (0.56)	230	Hospitalized, non-ICU	81	Hospitalized, ICU
	2021	Schonfelder	March–September/2020	Germany	Caucasian	239	141 (0.59)	164	Outpatients and hospitalized (non-ICU)	75	Hospitalized (ICU or mechanical ventilation) or dead
Alive × dead	2021	Alghamdi	—	Saudi Arabia	Saudi	861	—	784	Alive	77	Dead
	2021	Cuesta-Llavona	March–December/2020	Spain	Caucasian (Asturias)	484	276 (0.57)	114	Alive	38	Dead
Other	2020	Zhang	January–February/2020	China	—	80	33 (0.41)	56	Mild (hospitalized with fever, respiratory symptoms, and pneumonia seen with imaging)	24	Severe (RR ≥30/min; SpO ₂ ≤93%; PaO ₂ /FiO ₂ ≤300 mmHg; mechanical ventilation or ICU)
	2021	Alghamdi	—	Saudi Arabia	Saudi	861	—	457	Nonhospitalized	374	Hospitalized

Note. RR, respiratory rate; ICU, intensive care unit; SpO₂, oxygen saturation; PaO₂/FiO₂, arterial oxygen pressure/fraction of inspired oxygen.

(pooled OR: 1.45; 95% CI: 1.26–1.66) (**Figure 4A**). Homozygous deletion (D/D) carriers showed 49% increased odds to present severe COVID-19 compared with heterozygous (D/I) and homozygous insertion allele (I/I) carriers combined (pooled OR: 1.49, 95% CI: 1.22–1.83) (**Figure 4B**). On the other hand, the I/I genotype was protective against severe COVID-19 (pooled OR: 0.57, 95% CI: 0.45–0.74) (**Figure 4C**).

The *IFITM3* rs12252 meta-analysis with severity included three studies totaling 308 individuals admitted to an intensive care unit and 726 who were not admitted (**Table 3**). No significant association was observed under any genetic model (**Figure 5**). Meta-analysis for other outcomes with the *IFITM3* rs12252 could not be conducted. The *TNF-α* rs1800629 association with death was analyzed in three studies (**Table 4**), including 111 subjects who died and 1,095 survivors. No significant association was observed under the random-effect models (**Figure 6**). *FURIN* (**Table 5**) genetic variants had less than three studies; therefore, no meta-analyses were carried out.

DISCUSSION

We conducted a systematic review followed by meta-analysis including studies covering genetic association of COVID-19 susceptibility or prognosis with *IFITM3*, *FURIN*, *ACE1*, and *TNF-α* variants. Four studies included in the meta-analyses did not report the sample collection date, which is of particular interest in COVID-19 studies due to the emergence of variants of concern (VOCs) in the last part of 2020 (Konings et al., 2021). Some VOCs have been associated with higher viral load, worse prognosis, and lethality

(Davies et al., 2021; Faria et al., 2021), thus, confounding factors when evaluating genetic effects. Age can also be a confounding factor for COVID-19 association analysis (Fernández Villalobos et al., 2021). Most studies failed to conduct age-corrected estimation or even describe age separately for case and control groups. The same trend was observed for comorbidities (data now shown).

Ancestrality could also contribute to COVID-19 outcomes. Several studies do not present the ethnic background or, at least, the place of birth of the included subjects. Although heterogeneity was seen in parameters associated with ancestrality, the literature fails on genetic background diversity, an issue already raised for genomic data before (Popejoy and Fullerton, 2016). Another literature issue that needs attention is the selective reporting biases leading to the more likely publication of positive findings (Munafò et al., 2009; Sagoo et al., 2009).

We did not find an association of *IFITM3* rs12252 with Covid-19 severity. Our results corroborate the most extensive association study published to date since no significance was reported on any of chromosome 11 loci (Niemi et al., 2021). However, the second evaluated polymorphism, the *ACE1* rs4646994, showed significant effects with homozygous D carriers presenting higher odds of developing severe COVID-19. Several hits on the large arm of chromosome 17 have been previously reported (Niemi et al., 2021), although their genomic location is too far to hypothesize linkage disequilibrium. It is important to note that genome-wide data may find hits on loci that not necessarily are the ones harboring the causative variants because of its experimental design (Spencer et al., 2009). Furthermore, candidate-gene, whole-exome or whole-genome sequencing studies are more suitable in exploring large indel variants.

The *ACE1* rs4646994 has been associated with several clinical phenotypes, including COVID-19 (Castellon and Hamdi, 2007; Li




FIGURE 5 | Forest plot illustrating *IFITM3* rs12252 association with severity (non-ICU × ICU). No significant results were observed. Case and control definitions are presented in **Table 3**. **(A)** C allele association. **(B)** C recessive model. **(C)** T recessive model.

TABLE 4 | Association studies of *TNF-α* rs1800629 gene with COVID-19 prognosis or susceptibility included in the systematic review.

Year	Author	Sample					Control		Case	
		Date	Place	Ethnic background	Size	Male n(%)	n	Criteria	n	Criteria
2020	Saleh	April–July/2020	Egypt	—	1,084	600 (0.56)	184	Health care workers	900	COVID-19 positive
					900	-	444	Mild	456	Severe
					900	504 (0.56)	840	Alive	60	Dead
2021	Nia	June/2020–January/2021	Iran	—	550	234 (0.43)	275	COVID-19 negative	275	Hospitalized
					275	112 (0.41)	96	Nonsevere	179	Severe
					275	-	249	Alive	26	Dead
2021	Fishchuk	April–June/2020	Ukraine	—	31	16 (0.50)	25	Alive	6	Dead

et al., 2021). Most previous findings report associations with COVID-19 outcomes on a population level, indicating high variability on allelic frequencies across different populations (Delanghe et al., 2020; Pati et al., 2020; Yamamoto et al., 2020). On a molecular level, expression results indicate increased levels of ACE1 in D-allele carriers (Suehiro et al., 2004) with increased angiotensin II production (Hamdi and Castellon, 2004) and decreased ACE2 protein levels in lung tissue, thereby potentially affecting infectivity

by SARS-CoV-2 (Jacobs et al., 2021). Our group has previously indicated that lower ACE2 levels may increase the risk of COVID-19 respiratory distress (Rossi et al., 2021). Although there is a robust biological hypothesis linking *ACE1* rs4646994 with COVID-19, further reports are needed to understand better whether *ACE1* variants could contribute to COVID-19 severity. Moreover, studies are still required to adequately evaluate *IFITM3*, *FURIN*, and *TNF-α* genetic variants' role in COVID-19 susceptibility and outcomes.




TABLE 5 | Association studies of *FURIN* gene with COVID-19 prognosis or susceptibility included in the systematic review.

Year	Author	Sample					Control		Case	
		Date	Place	Ethnic background	Size	Male n(%)	n	Criteria	n	Criteria
2020	Latini	Mar–May/2020	Italy	–	–	–	–	Severe (respiratory impairment, requiring noninvasive ventilation)	–	Extremely severe (requiring invasive ventilation and ICU)
					131	82 (0.63)	–	Asymptomatic	–	Severe and extremely severe
2021	Torre-Fuentes	–	Spain	–	120	–	113	COVID-19 negative	7	COVID-19 positive

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

RS wrote the systematic review protocol. JA, DM, and RS conducted the systematic review. JA, RA, and RS drafted the manuscript. All authors revised and approved the final manuscript version.

ACKNOWLEDGMENTS

JA receives a FAPEMIG graduate fellowship. RA and RS are CNPq-Brazil Research Fellows.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fgene.2022.775246/full#supplementary-material>

REFERENCES

- Akbari, M., Taheri, M., Mehrpoor, G., Eslami, S., Hussien, B. M., Ghafouri-Fard, S., et al. (2022). Assessment of ACE1 Variants and ACE1/ACE2 Expression in COVID-19 Patients. *Vasc. Pharmacol.* 142, 106934. doi:10.1016/j.vph.2021.106934
- Aladag, E., Tas, Z., Ozdemir, B. S., Akbaba, T. H., Akpinar, M. G., Goker, H., et al. (2021). Human ACE D/I Polymorphism Could Affect the Clinicobiological Course of COVID-19. *J. Renin-Angiotensin-Aldosterone Syst.* 2021, 1–7. doi:10.1155/2021/5509280
- Alghamdi, J., Alaamery, M., Barhoumi, T., Rashid, M., Alajmi, H., Aljasser, N., et al. (2021). Interferon-induced Transmembrane Protein-3 Genetic Variant Rs12252 Is Associated with COVID-19 Mortality. *Genomics* 113, 1733–1741. doi:10.1016/j.ygeno.2021.04.002
- Amini-Bavil-Olyae, S., Choi, Y. J., Lee, J. H., Shi, M., Huang, I.-C., Farzan, M., et al. (2013). The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry. *Cell Host & Microbe* 13, 452–464. doi:10.1016/j.chom.2013.03.006
- Annunziata, A., Coppola, A., di Spirito, V., Cauteruccio, R., Marotta, A., Micco, P. D., et al. (2021). The Angiotensin Converting Enzyme Deletion/Deletion Genotype Is a Risk Factor for Severe COVID-19: Implication and Utility for Patients Admitted to Emergency Department. *Medicina* 57, 844. doi:10.3390/medicina57080844
- Araújo, J. L., Menezes, D., Saraiva-Duarte, J. M., Ferreira, L., Aguiar, R., and Souza, R. (2021). Systematic Review of Host Genetic Association with Covid-19 Prognosis and Susceptibility: What Have We Learned in 2020? *Rev. Med. Virol.* 32, e2283. doi:10.1002/rmv.2283
- Cafiero, C., Rosapepe, F., Palmirotta, R., Re, A., Ottaiano, M. P., Benincasa, G., et al. (2021). Angiotensin System Polymorphisms in SARS-CoV-2 Positive Patients: Assessment between Symptomatic and Asymptomatic Patients: A Pilot Study. *Pgpm* 14, 621–629. doi:10.2147/PGPM.S303666
- Castellon, R., and Hamdi, H. (2007). Demystifying the ACE Polymorphism: From Genetics to Biology. *Cpd* 13, 1191–1198. doi:10.2174/138161207780618902
- Cuesta-Llavona, E., Albaiceta, G. M., García-Clemente, M., Duarte-Herrera, I. D., Amado-Rodríguez, L., Hermida-Valverde, T., et al. (2021). Association between the Interferon-Induced Transmembrane Protein 3 Gene (IFITM3) Rs34481144/Rs12252 Haplotypes and COVID-19. *Curr. Res. Virol. Sci.* 2, 100016. doi:10.1016/j.crviro.2021.100016
- Davies, N. G., Jarvis, C. I., Jarvis, C. I., Edmunds, W. J., Jewell, N. P., Diaz-Ordaz, K., et al. (2021). Increased Mortality in Community-Tested Cases of SARS-CoV-2 Lineage B.1.1.7. *Nature* 593, 270–274. doi:10.1038/s41586-021-03426-1
- Deb, P., Zannat, K. e., Talukder, S., Bhuiyan, A. H., Jilani, M. S. A., and Saif-Ur-Rahman, K. M. (2022). Association of HLA Gene Polymorphism with Susceptibility, Severity, and Mortality of COVID -19: A Systematic Review. *Hla*. [online ahead of print]. doi:10.1111/tan.14560
- Delanghe, J. R., Speckaert, M. M., and de Buyzere, M. L. (2020). The Host's Angiotensin-Converting Enzyme Polymorphism May Explain Epidemiological Findings in COVID-19 Infections. *Clinica Chim. Acta* 505, 192–193. doi:10.1016/j.cca.2020.03.031
- Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., et al. (2021). Genomics and Epidemiology of the P.1 SARS-CoV-2 Lineage in Manaus, Brazil. *Science* 372, 815–821. doi:10.1126/science.abb2644
- Fernández Villalobos, N. V., Ott, J. J., Klett-Tammen, C. J., Bockey, A., Vanella, P., Krause, G., et al. (2021). Effect Modification of the Association between Comorbidities and Severe Course of COVID-19 Disease by Age of Study Participants: a Systematic Review and Meta-Analysis. *Syst. Rev.* 10, 194. doi:10.1186/s13643-021-01732-3
- Fishchuk, L., Rossokha, Z., Pokhylo, V., Cherniavska, Y., Tsvirenko, S., Kovtun, S., et al. (2021). Modifying Effects of TNF- α , IL-6 and VDR Genes on the Development Risk and the Course of COVID-19. Pilot Study. *Drug Metab. Personalized Ther.* [online ahead of print]. doi:10.1515/dmpt-2021-0127
- Gómez, J., Albaiceta, G. M., Cuesta-Llavona, E., García-Clemente, M., López-Larrea, C., Amado-Rodríguez, L., et al. (2021). The Interferon-Induced Transmembrane Protein 3 Gene (IFITM3) Rs12252 C Variant Is Associated with COVID-19. *Cytokine* 137, 155354. doi:10.1016/j.cyto.2020.155354
- Gómez, J., Albaiceta, G. M., García-Clemente, M., López-Larrea, C., Amado-Rodríguez, L., Lopez-Alonso, I., et al. (2020). Angiotensin-converting Enzymes (ACE, ACE2) Gene Variants and COVID-19 Outcome. *Gene* 762, 145102. doi:10.1016/j.gene.2020.145102
- Gong, P., Mei, F., Li, R., Wang, Y., Li, W., Pan, K., et al. (2022). Angiotensin-Converting Enzyme Genotype-specific Immune Response Contributes to the Susceptibility of COVID-19: A Nested Case-Control Study. *Front. Pharmacol.* 12, 759587. doi:10.3389/fphar.2021.759587
- Gunal, O., Sezer, O., Ustun, G. U., Ozturk, C. E., Sen, A., Yigit, S., et al. (2021). Angiotensin-converting Enzyme-1 Gene Insertion/deletion Polymorphism May Be Associated with COVID-19 Clinical Severity: A Prospective Cohort Study. *Ann. Saudi Med.* 41, 141–146. doi:10.5144/0256-4947.2021.141
- Hamdi, H. K., and Castellon, R. (2004). A Genetic Variant of ACE Increases Cell Survival: a New Paradigm for Biology and Disease. *Biochem. Biophysical Res. Commun.* 318, 187–191. doi:10.1016/j.bbrc.2004.04.004
- Hashan, M. R., Ghozy, S., El-Qushayri, A. E., Pial, R. H., Hossain, M. A., and al Kibria, G. M. (2021). Association of Dengue Disease Severity and Blood Group: A Systematic Review and Meta-analysis. *Rev. Med. Virol.* 31, 1–9. doi:10.1002/rmv.2147
- Hattersley, A. T., and McCarthy, M. I. (2005). What Makes a Good Genetic Association Study? *The Lancet* 366, 1315–1323. doi:10.1016/S0140-6736(05)67531-9
- Heidari Nia, M., Rokni, M., Mirinejad, S., Kargar, M., Rahdar, S., Sargazi, S., et al. (2021). Association of Polymorphisms in Tumor Necrosis Factors with SARS-CoV-2 Infection and Mortality Rate: A Case-control Study and In Silico Analyses. *J. Med. Virol* 94, 1502–1512. doi:10.1002/jmv.27477
- Hubacek, J. A., Dusek, L., Majek, O., Adamek, V., Cervinkova, T., Dlouha, D., et al. (2021). ACE I/D Polymorphism in Czech First-Wave SARS-CoV-2-Positive Survivors. *Clinica Chim. Acta* 519, 206–209. doi:10.1016/j.cca.2021.04.024
- Ioannidis, J. P. A., Ntzani, E. E., Trikalinos, T. A., and Contopoulos-Ioannidis, D. G. (2001). Replication Validity of Genetic Association Studies. *Nat. Genet.* 29, 306–309. doi:10.1038/ng749
- Jacobs, M., Lahousse, L., van Eeckhoutte, H. P., Wijnant, S. R. A., Delanghe, J. R., Brusselle, G. G., et al. (2021). Effect of ACE1 Polymorphism Rs1799752 on Protein Levels of ACE2, the SARS-CoV-2 Entry Receptor, in Alveolar Lung Epithelium. *ERJ Open Res.* 7, 00940–02020. doi:10.1183/23120541.00940-2020
- Karakaş Çelik, S., Çakmak Genç, G., Pişkin, N., Açıkgöz, B., Altinsoy, B., Kurucu İssiz, B., et al. (2021). Polymorphisms of ACE (I/D) and ACE2 Receptor Gene (Rs2106809, Rs2285666) Are Not Related to the Clinical Course of COVID-19: A Case Study. *J. Med. Virol.* 93, 5947–5952. doi:10.1002/jmv.27160
- Karki, R., and Kanneganti, T.-D. (2021). The 'cytokine Storm': Molecular Mechanisms and Therapeutic Prospects. *Trends Immunol.* 42, 681–705. doi:10.1016/j.it.2021.06.001
- Konings, F., Perkins, M. D., Kuhn, J. H., Pallen, M. J., Alm, E. J., Archer, B. N., et al. (2021). SARS-CoV-2 Variants of Interest and Concern Naming Scheme Conducive for Global Discourse. *Nat. Microbiol.* 6, 821–823. doi:10.1038/s41564-021-00932-w
- Kouhpayeh, H. R., Tabasi, F., Dehvari, M., Naderi, M., Bahari, G., Khalili, T., et al. (2021). Association between Angiotensinogen (AGT), Angiotensin-Converting Enzyme (ACE) and Angiotensin-II Receptor 1 (AGTR1) Polymorphisms and COVID-19 Infection in the Southeast of Iran: a Preliminary Case-Control Study. *Transl Med. Commun.* 6, 26. doi:10.1186/s41231-021-00106-0
- Latini, A., Agolini, E., Novelli, A., Borgiani, P., Giannini, R., Gravina, P., et al. (2020). COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells. *Genes* 11, 1010. doi:10.3390/genes11091010
- Li, M., Schifanella, L., and Larsen, P. A. (2021). Alu Retrotransposons and COVID-19 Susceptibility and Morbidity. *Hum. Genomics* 15, 2. doi:10.1186/s40246-020-00299-9
- Liu, S., Kong, C., Wu, J., Ying, H., and Zhu, H. (2012). Effect of CCR5- Δ 32 Heterozygosity on HIV-1 Susceptibility: A Meta-Analysis. *PLoS ONE* 7, e35020. doi:10.1371/journal.pone.0035020
- Mahmood, Z. S., Fadhil, H. Y., Abdul Hussein, T. A., and Ad'hiah, A. H. (2022). Severity of Coronavirus Disease 19: Profile of Inflammatory Markers and ACE (Rs4646994) and ACE2 (Rs2285666) Gene Polymorphisms in Iraqi Patients. *Meta Gene* 31, 101014. doi:10.1016/j.mgene.2022.101014
- Mir, M. M., Mir, R., Alghamdi, M. A. A., Alsayed, B. A., Wani, J. I., Alharthi, M. H., et al. (2021). Strong Association of Angiotensin Converting Enzyme-2 Gene Insertion/deletion Polymorphism with Susceptibility to Sars-Cov-2, Hypertension, Coronary Artery Disease and Covid-19 Disease Mortality. *Jpm* 11, 1098. doi:10.3390/jpm11111098

- Moher, D., Booth, A., and Stewart, L. (2014). How to Reduce Unnecessary Duplication: Use PROSPERO. *BJOG: Int. J. Obstet. Gy* 121, 784–786. doi:10.1111/1471-0528.12657
- Möhlendick, B., Schönfelder, K., Breuckmann, K., Elsner, C., Babel, N., Balfanz, P., et al. (2021). ACE2 Polymorphism and Susceptibility for SARS-CoV-2 Infection and Severity of COVID-19. *Pharmacogenetics and Genomics* 31, 165–171. doi:10.1097/FPC.0000000000000436
- Munafo, M. R., Stothart, G., and Flint, J. (2009). Bias in Genetic Association Studies and Impact Factor. *Mol. Psychiatry* 14, 119–120. doi:10.1038/mp.2008.77
- Nasserie, T., Hittle, M., and Goodman, S. N. (2021). Assessment of the Frequency and Variety of Persistent Symptoms Among Patients with COVID-19. *JAMA Netw. Open* 4, e2111417. doi:10.1001/jamanetworkopen.2021.11417
- Niemi, M. E. K., Karjalainen, J., Liao, R. G., Neale, B. M., Daly, M., Ganna, A., et al. (2021). Mapping the Human Genetic Architecture of COVID-19. *Nature* 600, 472–477. doi:10.1038/s41586-021-03767-x
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 Statement: an Updated Guideline for Reporting Systematic Reviews. *BMJ* 372, n71. doi:10.1136/bmj.n71
- Papadopoulou, A., Fragkou, P. C., Maratou, E., Dimopoulou, D., Kominakis, A., Kokkinopoulou, I., et al. (2022). Angiotensin-converting-enzyme Insertion/deletion Polymorphism, ACE Activity, and COVID-19: A rather Controversial Hypothesis. A Case-control Study. *J. Med. Virol.* 94, 1050–1059. doi:10.1002/jmv.27417
- Pati, A., Mahto, H., Padhi, S., and Panda, A. K. (2020). ACE Deletion Allele Is Associated with Susceptibility to SARS-CoV-2 Infection and Mortality Rate: An Epidemiological Study in the Asian Population. *Clinica Chim. Acta* 510, 455–458. doi:10.1016/j.cca.2020.08.008
- Peacock, T. P., Goldhill, D. H., Zhou, J., Baillon, L., Frise, R., Swann, O. C., et al. (2021). The Furin Cleavage Site in the SARS-CoV-2 Spike Protein Is Required for Transmission in Ferrets. *Nat. Microbiol.* 6, 899–909. doi:10.1038/s41564-021-00908-w
- Popejoy, A. B., and Fullerton, S. M. (2016). Genomics Is Failing on Diversity. *Nature* 538, 161–164. doi:10.1038/538161a
- Prabhu, S. S., Chakraborty, T. T., Kumar, N., and Banerjee, I. (2018). Association between IFITM3 Rs12252 Polymorphism and Influenza Susceptibility and Severity: A Meta-Analysis. *Gene* 674, 70–79. doi:10.1016/j.gene.2018.06.070
- Praissman, J. L., and Wells, L. (2021). Proteomics-Based Insights into the SARS-CoV-2-Mediated COVID-19 Pandemic: A Review of the First Year of Research. *Mol. Cell Proteomics* 20, 100103. doi:10.1016/j.mcpro.2021.100103
- Prelli Bozzo, C., Nchioua, R., Volcic, M., Koepke, L., Krüger, J., Schütz, D., et al. (2021). IFITM Proteins Promote SARS-CoV-2 Infection and Are Targets for Virus Inhibition *In Vitro*. *Nat. Commun.* 12, 4584. doi:10.1038/s41467-021-24817-y
- R Core Team (2014). *R Core Team (2014). R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing. Available at: <http://www.R-project.org/>.
- Rossi, Á. D., de Araújo, J. L. F., de Araújo, J. L. F., de Almeida, T. B., Ribeiro-Alves, M., de Almeida Velozo, C., et al. (2021). Association between ACE2 and TMPRSS2 Nasopharyngeal Expression and COVID-19 Respiratory Distress. *Sci. Rep.* 11, 9658. doi:10.1038/s41598-021-88944-8
- Saad, H., Jabotian, K., Sakr, C., Mahfouz, R., Akl, I. B., and Zgheib, N. K. (2021). The Role of Angiotensin Converting Enzyme 1 Insertion/Deletion Genetic Polymorphism in the Risk and Severity of COVID-19 Infection. *Front. Med.* 8, 798571. doi:10.3389/fmed.2021.798571
- Sago, G. S., Little, J., and Higgins, J. P. T. (2009). Systematic Reviews of Genetic Association Studies. *Plos Med.* 6, e1000028. doi:10.1371/journal.pmed.1000028
- Saleh, A., Sultan, A., Elashry, M. a., Farag, A., Mortada, M. I., Ghannam, M. A., et al. (2020). Association of TNF- α G-308 a Promoter Polymorphism with the Course and Outcome of COVID-19 Patients. *Immunological Invest.*, 1–12. doi:10.1080/08820139.2020.1851709
- Samprathi, M., and Jayashree, M. (2021). Biomarkers in COVID-19: An Up-To-Date Review. *Front. Pediatr.* 8, 607647. doi:10.3389/fped.2020.607647
- Schönfelder, K., Breuckmann, K., Elsner, C., Dittmer, U., Fistera, D., Herbstreit, F., et al. (2021). The Influence of IFITM3 Polymorphisms on Susceptibility to SARS-CoV-2 Infection and Severity of COVID-19. *Cytokine* 142, 155492. doi:10.1016/j.cyto.2021.155492
- Sohani, Z. N., Sarma, S., Alyass, A., de Souza, R. J., Robiou-du-Pont, S., Li, A., et al. (2016). Empirical Evaluation of the Q-Genie Tool: a Protocol for Assessment of Effectiveness. *BMJ Open* 6, e010403. doi:10.1136/bmjopen-2015-010403
- Spencer, C. C. A., Su, Z., Donnelly, P., and Marchini, J. (2009). Designing Genome-wide Association Studies: Sample Size, Power, Imputation, and the Choice of Genotyping Chip. *Plos Genet.* 5, e1000477. doi:10.1371/journal.pgen.1000477
- Sriram, K., and Insel, P. A. (2020). A Hypothesis for Pathobiology and Treatment of COVID-19: The Centrality of ACE1/ACE2 Imbalance. *Br. J. Pharmacol.* 177, 4825–4844. doi:10.1111/bph.15082
- Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., et al. (2020). COVID-19: Combining Antiviral and Anti-inflammatory Treatments. *Lancet Infect. Dis.* 20, 400–402. doi:10.1016/S1473-3099(20)30132-8
- Suehiro, T., Morita, T., Inoue, M., Kumon, Y., Ikeda, Y., and Hashimoto, K. (2004). Increased Amount of the Angiotensin-Converting Enzyme (ACE) mRNA Originating from the ACE Allele with Deletion. *Hum. Genet.* 115, 91. doi:10.1007/s00439-004-1136-4
- Sullivan, P. F. (2007). Spurious Genetic Associations. *Biol. Psychiatry* 61, 1121–1126. doi:10.1016/j.biopsych.2006.11.010
- Torre-Fuentes, L., Matias-Guiu, J., Hernández-Lorenzo, L., Montero-Escribano, P., Pytel, V., Porta-Etessam, J., et al. (2021). ACE2, TMPRSS2, and Furin Variants and SARS-CoV-2 Infection in Madrid, Spain. *J. Med. Virol.* 93, 863–869. doi:10.1002/jmv.26319
- Verma, S., Abbas, M., Verma, S., Khan, F. H., Raza, S. T., Siddiqi, Z., et al. (2021). Impact of I/D Polymorphism of Angiotensin-Converting Enzyme 1 (ACE1) Gene on the Severity of COVID-19 Patients. *Infect. Genet. Evol.* 91, 104801. doi:10.1016/j.meegid.2021.104801
- Yamamoto, N., Ariumi, Y., Nishida, N., Yamamoto, R., Bauer, G., Gojobori, T., et al. (2020). SARS-CoV-2 Infections and COVID-19 Mortalities Strongly Correlate with ACE1 I/D Genotype. *Gene* 758, 144944. doi:10.1016/j.gene.2020.144944
- Zhang, Y., Qin, L., Zhao, Y., Zhang, P., Xu, B., Li, K., et al. (2020). Interferon-Induced Transmembrane Protein 3 Genetic Variant Rs12252-C Associated with Disease Severity in Coronavirus Disease 2019. *J. Infect. Dis.* 222, 34–37. doi:10.1093/infdis/jiaa224

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 de Araújo, Menezes, Aguiar and Souza. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.